Concepedia

Norbert Hollaender

NH

Statistics

Publications

17

Citations

5.2K

H-Index

15

Active since

1997

Affiliations

Novartis (Switzerland)(Current)

Novartis (United States)

Istituti di Ricovero e Cura a Carattere Scientifico

Memorial Sloan Kettering Cancer Center

University Medical Center Freiburg

Norbert Hollaender is an author at Novartis (Switzerland) specializing in oncology, radiation oncology, and medicine.

ORCID

Top concepts

Publications per year

1997–2021

17

Publications

17

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

Robert J. Motzer, Bernard Escudier, Stéphane Oudard et al. · The Lancet · 2008 · 3K citations

, , +5

Phase 3 trial of everolimus for metastatic renal cell carcinoma

Robert J. Motzer, Bernard Escudier, Stéphane Oudard et al. · Cancer · 2010 · 1.1K citations

Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease

Robert Zeiser, Nicola Polverelli, Ron Ram et al. · New England Journal of Medicine · 2021 · 453 citations · Full text

A phase I–II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors

Patrick Schöffski, Peter Reichardt, Jean‐Yves Blay et al. · Annals of Oncology · 2010 · 139 citations · Full text

, , +6

Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts

Francesco Passamonti, Margherita Maffioli, Francisco Cervantes et al. · Blood · 2014 · 96 citations · Full text

1–5 of 17